Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma

Joshua D. Hansen,Matthew Correa,Mark A. Nagy,Matt Alexander,Veronique Plantevin,Virginia Grant,Brandon Wade Whitefield,Dehua Huang,Timothy Kercher,Roy L. Harris,Rama Krishna Narla,Jim Leisten,Yang Tang,Mehran F. Moghaddam,Katalin Ebinger,Joseph Piccotti,Courtney G. Havens,Brian E. Cathers,James Carmichael,Thomas O. Daniel,Rupert Vessey,Lawrence G. Hamann,Katerina Leftheris,Derek Mendy,Frans Baculi,Laurie LeBrun,Gody Khambatta,Antonia Lopez-Girona

Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma

2020

Many patients with multiple myeloma (MM) initially respond to treatment with modern combination regimens including immunomodulatory agents (lenalidomide and pomalidomide) and proteasome inhibitors....

Keywords:

Cancer research
Pomalidomide
Biochemistry
Chemistry
Ubiquitin ligase
Multiple myeloma
Refractory Multiple Myeloma
Proteasome
Lenalidomide

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations